Skip to main content
. 2019 Dec 6;107(3):521–529. doi: 10.1002/cpt.1678

Figure 5.

Figure 5

Sources of information of the signals prioritized and analyzed at the Pharmacovigilance Risk Assessment Committee from September 2012 to June 2018. EV, EudraVigilance; n/a, not applicable; PRAC, Pharmacovigilance Risk Assessment Committee; WHO, World Health Organization. *Excluding those counted already in categories above.